Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s):  CLAZF

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.


TSXV:CLAS.H - Post by User

Comment by indaknownewfieon Sep 25, 2018 6:27am
205 Views
Post# 28683438

RE:RE:Stock Options

RE:RE:Stock Options
PENNYPATROL wrote:

Kalytera Announces Grant of Stock Options to Directors and Employees

SAN FRANCISCO and TEL AVIV, Israel, Sept. 24, 2018 (GLOBE NEWSWIRE) -- Kalytera Therapeutics, Inc. (TSX VENTURE: KALY and OTCQB: KALTF) (the "Company" or "Kalytera") today announced that it has granted stock options on September 24, 2018 to certain directors and employees of the Company.  The stock options have an exercise price of $0.135 per common share and expire ten years from the date of grant.  One third of the options granted will vest on September 24, 2019 and the remaining options will vest in twenty-four (24) equal monthly installments commencing October 2019.

Stock options to purchase 1,262,475 common shares of Kalytera were issued to each of Ron Erickson, Jeff Paley and Gary Leong, who are all independent members of the Company’s board of directors, and stock options to purchase 5,117,794 common shares of Kalytera were issued to Robert Farrell, a director and the Chief Executive Officer of the Company.  Stock options to purchase 250,000 common shares of Kalytera were issued to Victoria Rudman, the Company’s Interim Chief Financial Officer, while Drs. Prutchi-Sagiv and Yeshurun were granted stock options to purchase 400,000 common shares and 500,000 common shares of the Company, respectively.

About Kalytera Therapeutics
Kalytera Therapeutics, Inc. is pioneering the development of cannabidiol (CBD) therapeutics. Through its proven leadership, drug development expertise, and intellectual property portfolio, Kalytera seeks to establish a leading position in the development of CBD medicines for a range of important unmet medical needs, with an initial focus on graft versus host disease (GVHD) and treatment of acute and chronic pain.

 
With the huge volume last week and and with the bullish chart and now stock options to board of directors, there is something enormous happening. Glta


Bullboard Posts